Conference abstractPublished 2019
LMP2/β 1i as tumor-suppressor defines new targets for uterine leiomyosarcoma therapy; PRUM-IBio study
National Hospital Organization Kyoto Medical Center, Japan Osaka City University Graduate School of Medicine, Japan Iida City Hospital, Japan Massachusetts Institute of Technology, USA Keio University School of Medicine, Japan<
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Uterine leiomyosarcoma (Ut-LMS) is resistant to chemotherapy and radiotherapy; therefore, surgical interventions are virtually the only means of clinical treatment. The prognosis of patients with Ut-LMS is poor and the 5-year survival rate is approximately 35%. Uterine leiomyoma (LMA) may occur in 70-80% of women by the age of 50 years. Difficulties have been reported in distinguishing Ut-LMS from other uterine mesenchymal tumors including uterine LMA and a diagnosis generally requires surgery and cytoscopy; therefore, a diagnostic method needs to be established that can identify non-standard smooth muscle differentiation. Exosomes are lipid-bilayer-enclosed extracellular vesicles that contain nucleic acids and proteins. They are secreted from all cells and circulate in the blood. Specific detection and isolation of tumor-cellderived exosomes in the circulation is currently lacking. Using molecular analyses, our research group identifies cellular factors, which are established as potential biomarker for Ut-LMS, specifically enriched in clinical materials derived from Pts with Ut-LMS. The molecular experiments demonstrated differential expression of cyclin E and P27/KIP1 that regulate cell-cycle G1 arrest via PSMB9/b1i expression. The discovery of differential expression of factors on a key cell-signaling pathway may provide new targets for diagnostic approaches and therapeutic intervention. Efficacy and reliability of immunohistological candidate-biomarker as a differential diagnosis for uterine mesenchymal tumor have been examined by large clinical study PRUM-IBio study. We will report a part of the results of this clinical study. These studies were conducted in accordance with university ethical guidelines.
Subjects
Pathology & Lab MedicineAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalArchives of Clinical Pathology
- SubjectPathology & Lab Medicine
- BylineArticles whose byline prints “Takuma Hayashi”
- BylineArticles whose byline prints “Tomoyuki Ichimura”
- BylineArticles whose byline prints “Kenji Sano”
- BylineArticles whose byline prints “Susumu Tonegawa”
- BylineArticles whose byline prints “Yae Kanai”
- BylineArticles whose byline prints “Dorit Zharhary”
- BylineArticles whose byline prints “Hiroyuki Aburatani”
- BylineArticles whose byline prints “Nobuo Yaegashi”
